BCR/ABL1 Kinase Domain Mutation

Real-time RT-PCR and directsequencing assays for detection of mutations associated with resistance toGleevec (imatinib) and other tyrosine kinase inhibitors, within the ABL1 kinasedomain of the BCR-ABL1 fusion gene of patients with chronicmyeloid leukemia or acute lymphoblastic leukemia. Common point mutations are T315I,Y253H, E255K/V, F359V/C/I, F317L/V/I/C, T315A, and V299L.

Synonyms
Turnaround Time
11 days
Methodology
Molecular
Specimen Requirements

Whole blood (3-5 mL), Bone marrow(1-2 mL), in Lavender-top (EDTA) tube.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible.

CPT Codes
81170